1 – 33 of 33
- show: 250
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Risk-adjusted benchmarking of long-term overall survival in patients with HER2-positive early-stage Breast cancer : A Swedish retrospective cohort study
(
- Contribution to journal › Article
- 2021
-
Mark
Variability in Breast Cancer Biomarker Assessment and the Effect on Oncological Treatment Decisions: A Nationwide 5-Year Population-Based Study
(
- Contribution to journal › Article
-
Mark
Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients with ERBB2-Positive Breast Cancer : A Phase 2 Randomized Clinical Trial
(
- Contribution to journal › Article
- 2020
-
Mark
Efficacy and safety of tailored and dose-dense adjuvant chemotherapy and trastuzumab for resected HER2-positive breast cancer : Results from the phase 3 PANTHER trial
(
- Contribution to journal › Article
-
Mark
MNK2 governs the macrophage antiinflammatory phenotype
2020) In Proceedings of the National Academy of Sciences of the United States of America 117(44). p.27556-27565(
- Contribution to journal › Article
- 2019
-
Mark
Impact of Epithelial-Stromal Interactions on Peritumoral Fibroblasts in Ductal Carcinoma in Situ
(
- Contribution to journal › Article
-
Mark
Ribosome biogenesis during cell cycle arrest fuels EMT in development and disease
(
- Contribution to journal › Article
- 2018
-
Mark
Identification and validation of single-sample breast cancer radiosensitivity gene expression predictors
(
- Contribution to journal › Article
-
Mark
Feasibility of reusing time-matched controls in an overlapping cohort
(
- Contribution to journal › Article
-
Mark
Dynamic evaluation of the immune infiltrate and immune function genes as predictive markers for neoadjuvant chemotherapy in hormone receptor positive, HER2 negative breast cancer
(
- Contribution to journal › Article
-
Mark
Spatially and functionally distinct subclasses of breast cancer-associated fibroblasts revealed by single cell RNA sequencing
(
- Contribution to journal › Article
-
Mark
Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancer
(
- Contribution to journal › Article
-
Mark
Assessment of early response biomarkers in relation to long-term survival in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab : Results from the Phase II PROMIX trial
(
- Contribution to journal › Article
-
Mark
Immune gene expression and response to chemotherapy in advanced breast cancer
(
- Contribution to journal › Article
- 2017
-
Mark
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
(
- Contribution to journal › Article
-
Mark
PAM50 provides prognostic information when applied to the lymph node metastases of advanced breast cancer patients
(
- Contribution to journal › Article
-
Mark
An HIF-1α/VEGF-A Axis in Cytotoxic T Cells Regulates Tumor Progression
(
- Contribution to journal › Article
-
Mark
Estimating the Risks of Breast Cancer Radiotherapy : Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized Trials
2017) In Journal of clinical oncology : official journal of the American Society of Clinical Oncology 35(15). p.1641-1649(
- Contribution to journal › Article
-
Mark
Societal challenges of precision medicine : Bringing order to chaos
(
- Contribution to journal › Article
- 2016
-
Mark
Expression of the chemokine CXCL14 in the tumour stroma is an independent marker of survival in breast cancer
(
- Contribution to journal › Article
-
Mark
Effect of tailored dose-dense chemotherapy vs standard 3-weekly adjuvant chemotherapy on recurrence-free survival among women with high-risk early breast cancer : A randomized clinical trial
(
- Contribution to journal › Article
- 2015
-
Mark
Highly reproducible results of breast cancer biomarkers when analysed in accordance with national guidelines - a Swedish survey with central re-assessment.
(
- Contribution to journal › Article
-
Mark
Contrasting breast cancer molecular subtypes across serial tumor progression stages: biological and prognostic implications.
(
- Contribution to journal › Article
-
Mark
Transcriptional profiling of breast cancer metastases identifies liver metastasis-selective genes associated with adverse outcome in luminal A primary breast cancer
(
- Contribution to journal › Published meeting abstract
-
Mark
Endothelial ALK1 Is a Therapeutic Target to Block Metastatic Dissemination of Breast Cancer.
(
- Contribution to journal › Article
- 2014
-
Mark
A Catalyst for Change: The European Cancer Patient's Bill of Rights.
2014) In The Oncologist(
- Contribution to journal › Article
- 2013
-
Mark
Prognostic Significance in Breast Cancer of a Gene Signature Capturing Stromal PDGF Signaling
(
- Contribution to journal › Article
- 2012
-
Mark
FACT: An Open-Label Randomized Phase III Study of Fulvestrant and Anastrozole in Combination Compared With Anastrozole Alone as First-Line Therapy for Patients With Receptor-Positive Postmenopausal Breast Cancer.
(
- Contribution to journal › Article
- 2011
-
Mark
A randomised feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer
(
- Contribution to journal › Article
- 2009
-
Mark
Prognostic Significance of Stromal Platelet-Derived Growth Factor beta-Receptor Expression in Human Breast Cancer
(
- Contribution to journal › Article
- 2007
-
Mark
Erythropoietin therapy and cancer related anaemia: updated Swedish recommendations
(
- Contribution to journal › Article
- 2006
-
Mark
Topoisomerase II{alpha} Gene Amplification Predicts Favorable Treatment Response to Tailored and Dose-Escalated Anthracycline-Based Adjuvant Chemotherapy in HER-2/neu-Amplified Breast Cancer: Scandinavian Breast Group Trial 9401.
(
- Contribution to journal › Article
-
Mark
Basoluminal carcinoma: A new biologically and prognostically distinct entity between basal and luminal breast cancer
(
- Contribution to journal › Article